In non-small cell lung cancer, YTHDF3 promotes immune suppression via PD-L1 upregulation [112], while in gastric cancer, it activates PI3K/AKT signaling and alters the tumor immune microenvironment [113]. This evidence concerns the gene AKT1 and neoplasm.